Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Insulin Resistance - Overview
Insulin Resistance - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Insulin Resistance - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Resistance - Companies Involved in Therapeutics Development
BioElectron Technology Corp
Caelus Health
F. Hoffmann-La Roche Ltd
Lixte Biotechnology Holdings Inc
NorthSea Therapeutics BV
Pfizer Inc
Recursion Pharmaceuticals Inc
Insulin Resistance - Drug Profiles
BioE-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDN-1163 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
englerin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FC-98 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Target hOGG1 for Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icosabutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7992 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildefil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Immunology, Metabolic Disorders and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Inherited Insulin Resistance Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYM-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-25659 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Insulin Resistance - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Insulin Resistance, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development for Insulin Resistance, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Insulin Resistance - Pipeline by BioElectron Technology Corp, H1 2019
Insulin Resistance - Pipeline by Caelus Health, H1 2019
Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Insulin Resistance - Pipeline by Lixte Biotechnology Holdings Inc, H1 2019
Insulin Resistance - Pipeline by NorthSea Therapeutics BV, H1 2019
Insulin Resistance - Pipeline by Pfizer Inc, H1 2019
Insulin Resistance - Pipeline by Recursion Pharmaceuticals Inc, H1 2019
Insulin Resistance - Dormant Projects, H1 2019
Insulin Resistance - Dormant Projects, H1 2019 (Contd..1), H1 2019